News

Valneva, a specialty vaccine company, and Pfizer Inc. today announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine…

We are happy to announce that the VBCF has got a new shareholder, the University of Vienna. This new liaison will open up new opportunities for…

Valneva and Dynavax Technologies Corporation announced their collaboration to initiate a vaccine program for the current coronavirus, COVID-19.

Austrian biotech company Calyxha Biotechnologies GmbH announced the grant of European Patent No. EP3383381.

The Austrian biotech incubator and accelerator CEBINA GmbH announces the initiation of several collaborative projects that address the global health…

We thank Michael Krebs, the long-term member of the VBCF supervisory board, for his engagement in VBCF’s development and his invaluable contribution…

The VBCF is a proud member of the VCDI - Vienna COVID-19 Diagnostic Initiative

The COVID-19 pandemic poses an enormous threat for healthcare systems and economies in Austria, Europe and the world. In this time of crisis,…

SARS-CoV-2, the virus causing coronavirus disease-19 (COVID-19), is spreading worldwide at a fast pace. In a concerted effort including researchers…

On March, 21st, 2020, Alwin Köhler was announced as the new Director of the Max Perutz Labs Vienna. He holds a joint Professorship for Molecular…

In a new study published in the Journal Science Advances, the Bell lab at IMBA reveals how multiple highly-conserved chromatin modifying complexes…

Valneva has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and agreed on the clinical development…